The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board and Organisational Changes

5 Mar 2013 07:00

RNS Number : 2036Z
PuriCore Plc
05 March 2013
 



PuriCore plc

("PuriCore" or the "Company")

5 March 2013

 

 

Board and Organisational Changes   

PuriCore (LSE: PURI), the water-based, clean technology company, today announces Board and organisational changes. Marella Thorell has been appointed Finance Director and will serve as an Executive Director with immediate effect and Peter Larkin, a leading key opinion leader in the US supermarket retail industry, has been appointed Non-Executive Director with effect from 1 April 2013.

 

Ms. Thorell, has been a key member of the PuriCore senior leadership team, most recently as Vice President of Human Resources and Administration and Company Secretary. She offers more than 24 years of experience in finance, operations, and human resources. Prior to joining PuriCore, she was the President of Thorell Consulting, a business consulting firm. Ms. Thorell was previously with Campbell Soup Company (NYSE: CPB), where she held a number of financial and management roles. She began her career and earned her CPA accounting qualification with Ernst & Young, LLP in Philadelphia. Ms. Thorell holds a BS in Business from Lehigh University.

Peter Larkin has more than 30 years of experience in the US supermarket retail industry. He is currently the President and CEO of the National Grocers Association, the national trade association representing independent retail and wholesale grocers of the food distribution industry. Prior to establishing his own government relations consulting firm in 2008, Mr. Larkin was the President and CEO of the California Grocers Association and Vice President of State Government Relations and Environmental Affairs for the Food Marketing Institute in Washington, DC. Previously, he managed government and media relations programs for The Kroger Co., the Tobacco Institute, and Philip Morris U.S.A. After earning a bachelor's degree in political science from the University of Vermont in 1976, he served as legislative assistant to U.S. Representative Donald Mitchell (R-NY).

 

The Company confirms that there is no additional information about Mr. Larkin or Ms. Thorell that the Company is required to disclose under paragraph 9.6.13(1) to (6) of the Listing Rules of the UK Listing Authority.

 

Michael Ashton, Executive Chairman, said:

"Marella has been instrumental to the growth and success of our US operations, and we are confident of her ability to provide strong financial leadership. Peter offers PuriCore extensive industry experience and will provide significant insight to our supermarket retail business, which accounts for nearly 50 per cent. of our total revenues. We welcome the contribution and guidance of both Marella and Peter, whose combined experience will be invaluable to the Company as we continue to grow the business in existing and new markets."

 

 

Enquiries:

UK

US

FTI Consulting

Sage Strategic Marketing

Susan Stuart/Simon Conway

Jennifer Guinan

Victoria Foster Mitchell

+1 610 410 8111

+44 (0) 20 7831 3113

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control including MRSA, e.Coli, and C. difficile. PuriCore is a leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore has operations in Malvern, Pennsylvania, US, and in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIAVSISIIV
Date   Source Headline
26th Mar 20197:00 amRNSCancellation of AIM Listing
25th Mar 20194:40 pmRNSSecond Price Monitoring Extn
25th Mar 20194:35 pmRNSPrice Monitoring Extension
20th Mar 201911:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Mar 201910:31 amRNSForm 8.5 (EPT/RI) Earthport Plc
18th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
15th Mar 20192:35 pmRNSResult of General Meeting
15th Mar 201910:09 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
14th Mar 201911:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Mar 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Mar 201911:53 amRNSForm 8.3 - Realm Therapeutics PLC
12th Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
8th Mar 201911:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Mar 201911:16 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Mar 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Mar 20199:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Mar 201911:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
1st Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Feb 201911:14 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Feb 20194:58 pmRNSForm 8.3 - Realm Therapeutics
27th Feb 20194:41 pmRNSSecond Price Monitoring Extn
27th Feb 20194:36 pmRNSPrice Monitoring Extension
27th Feb 201911:01 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
26th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Feb 201910:08 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
22nd Feb 201911:36 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
22nd Feb 201910:02 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Feb 20194:34 pmRNSForm 8.3 - Realm Therapeutics plc
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 201912:36 pmGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics Plc
21st Feb 20199:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Feb 201910:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Feb 20192:05 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
19th Feb 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Feb 20199:25 amRNSForm 8.5 (EPT/RI)Realm Therapeutics
18th Feb 20199:05 amRNSSecond Price Monitoring Extn
18th Feb 20199:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSBlock listing Interim Review
18th Feb 20197:00 amRNSUpdate on Strategic Review Re-release
15th Feb 20196:20 pmRNSUpdate on Strategic Review
15th Feb 20199:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Feb 20199:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Feb 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Feb 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Feb 201911:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.